Implementing Federated Analysis using DataSHIELD in the DREAM TO TREAT Atopic Dermatitis Registries Collaboration.

Many new biologic treatments and small molecule agents are emerging and being approved for treating atopic dermatitis (AD). Robust evidence, based on large sample sizes from real-world clinical settings, are needed to investigate the use of these new therapies, However, adequate sample sizes of patient data are difficult to obtain within one country alone, requiring international collaboration and data aggregation. To address this need for cooperative research, we investigated the feasibility for an international collaboration of registries to gather data from real-world clinical settings on patients' use of new systemic treatments for AD by creating a federated network between national registries that enables an analysis environment protecting privacy of information and ensuring compliance with General Data Protection Regulation.

Mechanistic in vivo studies of secondary skin-to-skin peanut allergen transfer to determine the impact of hand washing in reducing the risk of cutaneous sensitization.

Background: In Europe, 1-2% of children are diagnosed with a peanut allergy. Atopic dermatitis (AD) is a significant risk factor for food allergy development, with cutaneous allergen exposure playing a causative role in allergic sensitization, particularly in early childhood.

Objectives: To investigate the primary and secondary skin-to-skin transfer of peanut proteins and the impact of hand washing in reducing allergen transfer.

Methotrexate and ciclosporin both reduce levels of circulating IL-4 and IL-13 expressing CD4+ memory T-cells in childhood atopic dermatitis.

Atopic dermatitis (AD) is a chronic dermatosis characterised by type-2 inflammatory responses, skin barrier anomalies, and microbiome dysregulation. The variation of AD presentation necessitates a better understanding of the underlying disease mechanisms and the modulation of immune markers over a treatment course. Globally the most used systemic therapies for moderate-to-severe AD are methotrexate (MTX) and ciclosporin (CyA).

A pan-European register-based observational study of abrocitinib and conventional systemic therapies in moderate and severe atopic dermatitis: the DREAM TO TREAT AD study protocol.

Background: Atopic dermatitis (AD) is a common chronic inflammatory skin condition. Currently, there is a lack of real-world evidence regarding the effectiveness of systemic therapies for moderate-to-severe AD. Abrocitinib is a novel Janus kinase 1 selective inhibitor licensed for AD in adults and adolescents requiring systemic treatment.

Atopic dermatitis epidemiological research methodology: a global scoping review.

Background: Atopic dermatitis has the highest burden of all skin diseases globally. While numerous systematic reviews and meta-analyses have attempted to estimate the burden of atopic dermatitis at country, regional, and global levels, the variability in research methodology often leads to the exclusion of significant portions of data or the aggregation of data representing disparate factors. As a result, improving the understanding of the burden of atopic dermatitis requires a thorough review of the methodologies currently in use.

Atopic Dermatitis With Comorbid Skin Diseases: Recognition and Successful Treatment.

Atopic dermatitis (AD) is a common, chronic inflammatory skin disease that affects both children and adults. Atopic dermatitis is characterized by pruritus, erythema, induration, and scale, which can present with other conditions that may mimic or complicate AD; often leading to diagnostic challenges. Differential diagnoses include seborrheic dermatitis, contact dermatitis, psoriasis, infections, inflammatory/autoimmune disorders, cutaneous T-cell lymphoma, and immunodeficiency-related dermatoses; to name a few.

Gene-Environment Interaction Affects Risk of Atopic Eczema: Population and In Vitro Studies.

Background: Multiple environmental and genetic factors play a role in the pathogenesis of atopic eczema (AE). We aimed to investigate gene-environment interactions (G × E) to improve understanding of the pathophysiology.

Methods: We analysed data from 16 European studies to test for interaction between the 24 most significant AE-associated loci identified from genome-wide association studies and 18 early-life environmental factors.

Living network meta-analysis to compare nemolizumab against other available targeted systemic treatments for atopic dermatitis.

Nemolizumab is a new biologic approved to treat atopic dermatitis. In this perspective piece, we use results from our living systematic review and network meta-analysis to provide perspective on the relative efficacy of nemolizumab compared with other approved targeted systemic treatments.

Skin Microbiome Dynamics in Atopic Dermatitis: Understanding Host-Microbiome Interactions.

Atopic dermatitis (AD) is a chronic inflammatory skin disorder affecting both children and adults, characterized by pruritus, eczematous lesions, and compromised skin barrier function. A key feature of AD is dysbiosis of the skin microbiome, marked by reduced microbial diversity and the overgrowth of in lesional skin. exacerbates skin barrier dysfunction and immune dysregulation, leading to recurrent infections and disease flares.

Exposure-response of ciclosporin and methotrexate in children and young people with severe atopic dermatitis: a secondary analysis of the TREatment of severe Atopic dermatitis Trial (TREAT).

This is a secondary analysis of a multicentre randomized controlled trial of ciclosporin and methotrexate in children and young people (CYP) with severe atopic dermatitis (AD). Longitudinal trough ciclosporin and erythrocyte methotrexate polyglutamate (MTX-PG) concentrations were measured to evaluate their associations with treatment response and adverse events. Both ciclosporin (4 mg kg-1 daily) and methotrexate (0.

The Prevalence and Severity of Hand Eczema Among Adults in Tasiilaq, East Greenland.

Background: Hand eczema (HE) is described as a common disease in Greenland, but studies on its epidemiology and severity are lacking.

Objectives: To investigate the point prevalence and severity of HE among adults in East Greenland in relation to age, sex, and occupation.

Methods: In May 2022, we conducted a cross-sectional study in Tasiilaq, East Greenland.

Integrated Efficacy and Safety Analysis of Abrocitinib in Adolescents With Moderate-to-Severe Atopic Dermatitis.

Background: Abrocitinib has demonstrated long-term efficacy (48 weeks) and safety (~4 years) in adults and adolescents with moderate-to-severe atopic dermatitis (AD). This analysis evaluated abrocitinib efficacy in adolescents through 112 weeks, and safety of up to 4.6 years of exposure.

Impact of sensitive skin on quality of life, anxiety and depression: a cross-sectional study.

Background: Sensitive skin (SS) is a common condition reported by many people worldwide. Patient interviews reveal that individuals with SS experience diminished quality of life, anxiety and depression. Nonetheless, the impact of SS on mental health remains unclear.

A Case Series of Refractory Pediatric Atopic Dermatitis Effectively Treated With Dupilumab in Combination With Abrocitinib.

Children with severe atopic dermatitis (AD), refractory to conventional systemic treatment as well as single-agent biologic and Janus kinase inhibitor (JAKi) such as abrocitinib, currently face a lack of treatment options. In response to this clinical conundrum, we present three cases of severe and refractory pediatric AD successfully managed with combined dupilumab and abrocitinib. These children had exhausted all conventional treatments and had undergone treatment with both dupilumab and abrocitinib individually, as well as dupilumab in conjunction with methotrexate.

International consensus on methotrexate dosing for patients with atopic dermatitis: An eDelphi study.

Background: Despite the widespread off-label use of methotrexate (MTX) for the treatment of atopic dermatitis (AD), there is limited high-quality evidence on dosing regimens and existing guidelines do not provide clear recommendations regarding dosing strategies.

Objective: The aim of this study was to achieve international consensus among AD experts to standardize the dosing regimen for MTX treatment in adults and children with AD.

Methods: An electronic Delphi (eDelphi) study was conducted from October 2021 to September 2022.